| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Neuroendocrine Tumors | |||||
| 2 | More general conditions related to this trial | ||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms, Germ Cell and Embryonal | |||||
| Neoplasms, Nerve Tissue | |||||
| Neuroectodermal Tumors | |||||
| 3 | Interventions listed in this trial | ||||
| sorafenib and cyclophosphamide | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Cyclophosphamide | |||||
| Sorafenib | |||||
| 5 | More general drug interventions related to this trial | ||||
| Alkylating Agents | |||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Alkylating | |||||
| Antirheumatic Agents | |||||
| Enzyme Inhibitors | |||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Myeloablative Agonists | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Protein Kinase Inhibitors | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| University Health Network, Toronto | |||||
|
